Abstract
The study of tachykinin NK1 (substance P) receptor antagonists has emerged as a field of great promise due to accumulating evidence that NK1 antagonists offer possible new treatment options in therapeutic areas ranging from pain, emesis, and pulmonary disorders to depression and anxiety. It is hoped that the unique mechanism of action of these agents, which involves modulation of effects mediated by the interaction of the neuropeptide substance P with its Gprotein coupled receptor, will provide improvements over existing therapies. For this reason many pharmaceutical companies are engaged in intense research programs with the goal of bringing safe and effective new drugs to the market. To date a wealth of diverse NK1 antagonists have been discovered, several of which have been evaluated in clinical trials. Despite rich structural diversity in this area of medicinal chemistry a number of structural features are commonly shared amongst otherwise unrelated antagonists. This theme and others are covered with the aim of conveying recent successful approaches to the discovery of potent and selective nonpeptide NK1 antagonists. This review focuses mainly on reports appearing in the year 2001 and the first half of 2002.
Keywords: substance p, neurokinin, tachykinin, nk1 antagonist, depression, emesis, anxiety
Current Topics in Medicinal Chemistry
Title: Medicinal Chemistry of Selective Neurokinin-1 Antagonists
Volume: 3 Issue: 12
Author(s): John M. Humphrey
Affiliation:
Keywords: substance p, neurokinin, tachykinin, nk1 antagonist, depression, emesis, anxiety
Abstract: The study of tachykinin NK1 (substance P) receptor antagonists has emerged as a field of great promise due to accumulating evidence that NK1 antagonists offer possible new treatment options in therapeutic areas ranging from pain, emesis, and pulmonary disorders to depression and anxiety. It is hoped that the unique mechanism of action of these agents, which involves modulation of effects mediated by the interaction of the neuropeptide substance P with its Gprotein coupled receptor, will provide improvements over existing therapies. For this reason many pharmaceutical companies are engaged in intense research programs with the goal of bringing safe and effective new drugs to the market. To date a wealth of diverse NK1 antagonists have been discovered, several of which have been evaluated in clinical trials. Despite rich structural diversity in this area of medicinal chemistry a number of structural features are commonly shared amongst otherwise unrelated antagonists. This theme and others are covered with the aim of conveying recent successful approaches to the discovery of potent and selective nonpeptide NK1 antagonists. This review focuses mainly on reports appearing in the year 2001 and the first half of 2002.
Export Options
About this article
Cite this article as:
Humphrey M. John, Medicinal Chemistry of Selective Neurokinin-1 Antagonists, Current Topics in Medicinal Chemistry 2003; 3 (12) . https://dx.doi.org/10.2174/1568026033451925
DOI https://dx.doi.org/10.2174/1568026033451925 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Complications of Obesity
Current Respiratory Medicine Reviews Preface [Hot Topic:Inflammatory Markers and Mediators: Emerging Therapeutic Targets in Diabetes, Cardiovascular and Metabolic Disorders (Guest Editor: Samuel Dagogo-Jack, MD)].
Current Drug Targets Immune System, Cell Senescence, Aging and Longevity - Inflamm-Aging Reappraised
Current Pharmaceutical Design Non-Cholinergic Pharmacotherapy Approaches to Alzheimers Disease: The Use of Non-Steroidal Anti-Inflammatory Drugs
CNS & Neurological Disorders - Drug Targets Perspective of Molecular Hydrogen in the Treatment of Sepsis
Current Pharmaceutical Design Concepts for Nano-delivery of Therapeutic Immunomodulatory Agents
Current Bionanotechnology (Discontinued) Potential Disease Targets for Drugs that Disrupt Protein - Protein Interactions of Grb2 and Crk Family Adaptors
Current Pharmaceutical Design Gene Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Subject Index To Volume 6
Current Gene Therapy Computer-Aided Drug Design Applied to Secondary Metabolites as Anticancer Agents
Current Topics in Medicinal Chemistry The Role of Lifestyle Change in the Prevention and Treatment of NAFLD
Current Pharmaceutical Design The Cholinergic Potential, the Vagus Nerve and Challenges in Treatment of Traumatic Brain Injury
Current Pharmaceutical Design Hypericin - The Facts About a Controversial Agent
Current Pharmaceutical Design Advancement in Microsponge Drug Delivery System: Preparation Methods, Patents and Commercial Utility
Recent Patents on Drug Delivery & Formulation Centenarian Offspring: A Model for Understanding Longevity
Current Vascular Pharmacology Ganoderma lucidum: A Potential for Biotechnological Production of Anti-Cancer and Immunomodulatory Drugs
Recent Patents on Anti-Cancer Drug Discovery Protein Kinases as Drug Targets in Human and Animal Diseases
Current Enzyme Inhibition Evidence on the Protective Role of High-Density Lipoprotein (HDL) in HIV-Infected Individuals
Current Vascular Pharmacology The Multiple Facets of Hematopoietic Stem Cells
Current Neurovascular Research Chemoprevention of Colorectal Carcinogenesis by Natural Anti-Inflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry